Cell line name |
SR DU-145 |
Synonyms |
SR DU 145; SR DU145 |
Accession |
CVCL_4901 |
Resource Identification Initiative |
To cite this cell line use: SR DU-145 (RRID:CVCL_4901) |
Comments |
Population: Caucasian. Selected for resistance to: ChEBI; CHEBI:45906; Suramin. Derived from site: Metastatic; Brain; UBERON=UBERON_0000955. |
Sequence variations |
- Mutation; HGNC; 1787; CDKN2A; Simple; p.Asp84Tyr (c.250G>T) (p.Arg98Leu, c.293G>T); ClinVar=VCV000376306; Zygosity=Homozygous (from parent cell line).
- Mutation; HGNC; 9884; RB1; Simple; p.Lys715Ter (c.2143A>T); ClinVar=VCV001786615; Zygosity=Homozygous (from parent cell line).
- Mutation; HGNC; 11389; STK11; Simple; p.Lys178fs*86 (c.532_536delAAGCC); Zygosity=Homozygous (from parent cell line).
- Mutation; HGNC; 11998; TP53; Simple; p.Pro223Leu (c.668C>T); ClinVar=VCV000234214; Zygosity=Heterozygous (from parent cell line).
- Mutation; HGNC; 11998; TP53; Simple; p.Val274Phe (c.820G>T); ClinVar=VCV000376674; Zygosity=Heterozygous (from parent cell line).
|
Disease |
Prostate carcinoma (NCIt: C4863) |
Species of origin |
Homo sapiens (Human)
(NCBI Taxonomy: 9606) |
Hierarchy |
Parent: CVCL_0105 (DU145) |
Sex of cell |
Male |
Age at sampling |
69Y |
Category |
Cancer cell line |
Publications | PubMed=9923549; DOI=10.1007/s002800050884 Church D., Zhang Y.-L., Rago R.P., Wilding G. Efficacy of suramin against human prostate carcinoma DU145 xenografts in nude mice. Cancer Chemother. Pharmacol. 43:198-204(1999) PubMed=15643172; DOI=10.1097/01.ju.0000141580.30910.57 Sobel R.E., Sadar M.D. Cell lines used in prostate cancer research: a compendium of old and new lines -- part 1. J. Urol. 173:342-359(2005) |
Cross-references |
Cell line databases/resources |
cancercelllines; CVCL_4901
|
Encyclopedic resources |
Wikidata; Q54955623
|
Entry history |
Entry creation | 04-Apr-2012 |
Last entry update | 05-Oct-2023 |
Version number | 21 |
---|